fi cient to cause the sustained systemic immunosuppression that would be responsible for lymphomas [1] . This is true even in young children with moderate-to-severe dermatitis affecting a large body surface area [2] .
There is no evidence of photocarcinogenic or mutagenic potential in animals treated with pimecrolimus. Neither pimecrolimus nor tacrolimus have been associated with an increased risk of malignancies in clinical studies [1] .
From clinical use in over 7.5 million patients treated with one or the other medication, very few cases of malignancies have been reported. The number is well below the expected background incidence in the population treated, even taking into account under-reporting [1] .
Those lymphomas identifi ed by spontaneous adverseevent reporting systems do not have the clinical presentation and histology that characterize lymphomas occurring in the setting of immunosuppressive therapy. In contrast, lymphomas that have the characteristics of disease related to systemic immunosuppression have only been Over the last decade, both agents have been extensively studied in clinical trials involving almost 40,000 patients, and their effi cacy and safety in the treatment of atopic dermatitis have been demonstrated. More than 7.5 million patients, over half of them children, have been treated with these medications since their approval.
Systemic absorption of both drugs is very limited and even though blood concentrations have been detected in some patients, the values are usually very low and insuf- observed in animals exposed to high systemic levels of calcineurin inhibitors. These animals experienced systemic exposure that is much greater than can be achieved with topical application in humans [1] .
There is no increased incidence of systemic infections in patients treated with topical calcineurin inhibitors [1] .
There is no evidence of systemic immunosuppression from topical pimecrolimus or tacrolimus as measured by response to vaccination and delayed-type hypersensitivity [3] [4] [5] .
Atopic dermatitis is a chronic, recurring and frustrating condition. Many patients suffer from atopic dermatitis on the face and sensitive skin sites where long-term application of topical corticosteroids is not indicated.
The health and safety of patients are of paramount importance to physicians. We are concerned that the aforementioned warnings confuse and unnecessarily worry patients and their families, as well as health-care providers. Current labeling suffi ciently describes the appropriate use and safety of these medications. We strongly believe that the recent recommendations of the Pediatric Advisory Committee and the FDA Health Alert are not justifi ed based on the scientifi c evidence and should be reconsidered.
